NCT00270699View on ClinicalTrials.gov

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Dengue Fever
Interventions
BIOLOGICAL

rDEN4delta30-200,201

Live attenuated dengue 4 vaccine (one of three doses)

BIOLOGICAL

Placebo

Placebo for rDEN4delta30-200,201

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00270699 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults | Biotech Hunter | Biotech Hunter